Document:

Amendment No.1 to Master Security Agreement dated May 1, 2000

 Exhibit 10.12 
  
 AMENDMENT 
  
 THIS AMENDMENT is made as of the 1st day of May, 2000, between General Electric Capital Corporation (“Secured Party”) and Xcyte Therapies, Inc. (“Debtor”) in connection with that certain Master Security Agreement dated
or dated as of May 1, 2000 (“Agreement”). The terms of this Agreement are hereby incorporated into the Agreement as though fully set forth therein. Section references below refer to the section numbers of the Agreement. The
Agreement is hereby amended as follows: 
  
 2.
REPRESENTATIONS, WARRANTIES AND COVENANTS OF DEBTOR. 
  
 Delete subsection (i) and replace with the following: 
  
 “(i) The Collateral is, and will remain, in good condition and repair, subject to ordinary wear and tear.” 
  
 3. COLLATERAL. 
  
 In subsection (b)(ii) after “all of the Collateral in”, insert “reasonably”. 
  
 “(c) Debtor shall not, without the prior written
consent of Secured Party, (i) part with possession of any of the Collateral (except to Secured Party or for maintenance and repair), (ii) remove any of the Collateral from the address specified in the Collateral Schedule, or (iii) sell, rent, lease,
mortgage, grant a security interest in or otherwise transfer or encumber (except for Permitted Liens) any of the Collateral.” 
  
 In subsection (d), line 1 after “when due all taxes” insert “(excluding taxes on Secured Party’s income)”. 
  
 4. INSURANCE. 
  
 In line 4, insert “reasonably” before “acceptable to Secured
Party.” Also, in line 4, before “Debtor shall deliver”, insert the sentence “The deductible amount will not exceed $1,000 per occurrence.” 
  
 In subsection (b), line 6, delete “thirty (30) days” and replace with “twenty (20)” days. 
  
 In subsection (b), line 7, before “Debtor appoints Secured Party”,
insert “In the event of default by Debtor under this Agreement,” 
  
 In subsection (b), line 9, after “Debtor is in default”, insert “under this Agreement”. Also in line 9, before “Proceeds of insurance shall be applied”, insert “After consultation
with Debtor,”. 
  
 5. REPORTS. 
  
 Delete Section 5 and replace with the following: 
  
 “5. REPORTS. 
  
 (a) Debtor shall promptly notify Secured Party of (i) any change in the name
of Debtor, (ii) any relocation of its chief executive offices, (iii) any relocation of any Collateral, which relocation may not be made unless Debtor has obtained the prior written consent of Secured Party, (iv) any of the Collateral being lost,
stolen, missing, destroyed, materially damaged or worn out, or (v) any lien, claim or encumbrance other than Permitted Liens attaching to or being made against any of the Collateral. 
  
 (b) Debtor will deliver to Secured Party financial statements as follows. If Debtor is privately held company, then Debtor
agrees to provide monthly financial statements, certified by Debtor’s chief financial officer including a balance sheet, and statement of operations within 30 days of each month end, and its complete audited annual financial statements,
including a balance sheet, statement of operations and cash flow statement, certified by a recognized firm of certified public accountants, at 

  

 
such time as Debtor’s Board of Directors receives the audit, but in no event later than 180 days from Debtors’ fiscal year end. If Debtor is a
publicly held company, then Debtor agrees to provide quarterly and annual audited statements, certified by a recognized firm of certified public accountants, within 10 days after the statements are provided to the Securities and Exchange Commission
(“SEC”). All such statements are to be prepared using generally accepted accounting principles and, if Debtor is a publicly held company, are to be in compliance with SEC requirements.” 
  
 6. FURTHER ASSURANCES. 
  
 In subsection (b), line 1, before “Debtor irrevocably grants”,
insert “Only in the event of Debtor’s default under this Agreement,”. 
  
 In subsection (c), line 2, after “without limitation, related” insert “reasonable”. 
  
 7. DEFAULT AND REMEDIES. 
  
 In subsection (a) (i), after “obligation to pay”, insert “within ten (10) days of the date”. 
  
 In subsection (a) (vi), line 2, after “or any of the Collateral”,
insert “and not discharged or dismissed within (30) days of commencement and”. 
  
 In subsection (a) (vii), insert the following after “Secured Party” and before the semicolon: “and all applicable notice and cure periods have lapsed”. 
  
 In subsection (c) (ii), after “legal process”, insert “to the
extent permitted by applicable law”. 
  
 In subsection (c)
(iii), before “sell the Collateral”, insert “after five (5) days written notice to Debtor by registered or certified mail,”. 
  
 In subsection (d), line 4, after “liable for any”, insert “remaining”. 
  
 8. MISCELLANEOUS. 
  
 In subsection (a), line 1, after “may be assigned” insert “(without changing the terms of this Agreement or any other document
assigned)”. 
  
 TERMS USED, BUT NOT OTHERWISE DEFINED HEREIN
SHALL HAVE THE MEANINGS GIVEN TO THEM IN THE AGREEMENT. EXCEPT AS EXPRESSLY AMENDED HEREBY, THE AGREEMENT SHALL REMAIN IN FULL FORCE AND EFFECT. IF THERE IS ANY CONFLICT BETWEEN THE PROVISIONS OF THE AGREEMENT AND THIS AMENDMENT, THEN THIS AMENDMENT
SHALL CONTROL. 
  
 IN WITNESS WHEREOF, the parties hereto
have executed this Amendment simultaneously with Agreement by signature of their respective authorized representative set forth below. 
  

									
	General Electric Capital Corporation	 	 	 	Xcyte Therapies, Inc.
					
	 By:
	 	 /s/ Barbara Kaiser
	 	 	 	 By:
	 	 /s/ Ronald J. Berenson

	 Title:
	 	 EVP/GM
	 	 	 	 Title:
	 	 President & CEOAmendment No.2 to Master Security Agreement

 Exhibit 10.13 
  
 AMENDMENT NO. 2 
  
 THIS AMENDMENT NO. 2 is made as of the 18th day of August 2004, between General Electric Capital Corporation (“Secured Party”) and Xcyte
Therapies, Inc. (“Debtor”) in connection with that certain Master Security Agreement and Amendment, dated as of May 1, 2000 (“Agreement”). The terms of this Amendment No. 2 are hereby incorporated into the Agreement as though
fully set forth therein. Section references below refer to the section numbers of the Agreement. The Agreement is hereby amended to add the following events of default to Section 7(a): 
  
 “(xii) Debtor’s improper filing of an amendment or termination statement relating to a filed financing statement
describing the Collateral without the prior written consent of the Secured Party ; 
  
 (xiii) There is a material adverse change in the Debtor’s financial condition, which would materially impair the ability of Debtor to perform its material obligations hereunder, as determined solely, reasonably
and in good faith by Secured Party; 
  
 (xiv) Any Guarantor
revokes or attempts to revoke its guaranty of any of the Indebtedness or fails to observe or perform any material covenant, condition or agreement to be performed under any guaranty or other related document to which it is a party; 
  
 (xv) Debtor defaults under any other material obligation totaling at least
$500,000 for (A) borrowed money, (B) the deferred purchase price of property or (C) payments due under any lease agreement, unless Debtor cures any such defaults within 30 days; or 
  
 (xvi) At any time during the term of this Agreement Debtor sells all or substantially all of its assets without Secured
Party’s prior written consent. 
  
 TERMS USED, BUT NOT
OTHERWISE DEFINED HEREIN SHALL HAVE THE MEANINGS GIVEN TO THEM IN THE AGREEMENT. EXCEPT AS EXPRESSLY AMENDED HEREBY, THE AGREEMENT SHALL REMAIN IN FULL FORCE AND EFFECT. IF THERE IS ANY CONFLICT BETWEEN THE PROVISIONS OF THE AGREEMENT AND THIS
AMENDMENT NO. 2, THEN THIS AMENDMENT NO. 2 SHALL CONTROL. 
  
 IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 2 simultaneously with the Agreement by signature of their respective authorized representative set forth below. 
  

									
	General Electric Capital Corporation	 	 	 	Xcyte Therapies, Inc.
					
	 By:
	 	 /s/ Diane Earle
	 	 	 	 By:
	 	 /s/ Kathi Cordova

	 Name:
	 	 Diane Earle
	 	 	 	 Name:
	 	 Kathi Cordova

	 Title:
	 	 Senior Vice President
	 	 	 	 Title:
	 	 Senior VP Finance & TreasurerForm of Notice of Option Grant and Agreement  for 1996 Stock Option Plan

 Exhibit 10.20 
  
 XCYTE THERAPIES, INC. 
  
 AMENDED AND RESTATED 1996 STOCK PLAN 
  
 NOTICE OF STOCK OPTION GRANT AND STOCK OPTION AGREEMENT 
  
 Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Option Agreement. 
  

	I.	NOTICE OF STOCK OPTION GRANT 

  
 «Optionee» 
 «Address1» 
 «Address2» 
  
 The undersigned Optionee has been granted an Option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan
and this Option Agreement, as follows: 
  

			
	Board Approval Date:	 	«BoardApprovalDate»
		
	Date of Grant:	 	«DateofGrant»
		
	Vesting Commencement Date:	 	«VestingDate»
		
	Exercise Price per Share:	 	$«ExercisePrice»
		
	Total Number of Shares Granted:	 	«NoofShares»
		
	Total Exercise Price:	 	$«TotalPrice»
		
	Type of Option:	 	«TypeofOption»
		
	Term/Expiration Date:	 	«ExpirationDate»
		
	Vesting Schedule:	 	«Vesting»

  
 Termination Period: 
  
 The Option shall remain exercisable for
three (3) months following the Optionee’s termination. In the case of an Incentive Stock Option, such period of time for exercise shall not exceed three (3) months from the date of termination of employment or consulting relationship, or such
longer period as may be applicable upon death or Disability of Optionee as provided in the Plan, but in no event 

  

 
later than the Term/Expiration Date as provided above. If, on the date of termination, the Optionee is not entitled to exercise the Optionee’s entire
Option, the Shares covered by the unexercisable portion of the Option shall revert to the Plan. If, after termination, the Optionee does not exercise his or her Option within the time specified by the Administrator, the Option shall terminate, and
the Shares covered by such Option shall revert to the Plan. 
  

	II.	AGREEMENT 

  
 1. Grant of Option. The Plan Administrator of the Company hereby grants to the Optionee named in the Notice of Grant (the
“Optionee”), an option (the “Option”) to purchase the number of Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the “Exercise Price”), and
subject to the terms and conditions of the Plan, which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan shall prevail.

  
 If designated in the Notice of Grant as an Incentive Stock
Option (“ISO”), this Option is intended to qualify as an Incentive Stock Option as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this Option shall be
treated as a Nonstatutory Stock Option (“NSO”). 
  
 2. Exercise of Option. 
  
 (a)
Right to Exercise. This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Grant and with the applicable provisions of the Plan and this Option Agreement. 
  
 (b) Method of Exercise. This Option shall be
exercisable by delivery of an exercise notice in the form attached as Exhibit A (the “Exercise Notice”) which shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised,
and such other representations and agreements as may be required by the Company. The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares. This Option shall be deemed to be exercised upon receipt
by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price. No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such exercise complies with Applicable laws. Assuming such
compliance, for income tax purposes the Shares shall be considered transferred to the Optionee on the date on which the Option is exercised with respect to such Shares. 
  
 3. [Intentionally left blank] 
  
 4. [Intentionally left blank] 
  
 5. Method of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of the
Optionee: 
  
 (a) cash or check; 
  

 -2- 

 (b) consideration received by the Company under a formal cashless exercise program
adopted by the Company in connection with the Plan; or 
  
 (c) surrender of other Shares which, (i) in the case of Shares acquired upon exercise of an option, have been owned by the Optionee for more than six (6) months on the date of surrender, and (ii) have a Fair Market Value on the date of
surrender equal to the aggregate Exercise Price of the Exercised Shares. 
  
 6. Restrictions on Exercise. This Option may not be exercised until such time as the Plan has been approved by the shareholders of the Company, or if the issuance of such Shares upon such exercise or the method
of payment of consideration for such shares would constitute a violation of any Applicable Law. 
  
 7. Non-Transferability of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution
and may be exercised during the lifetime of Optionee only by Optionee. The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee. 
  
 8. Term of Option. This Option may be exercised only within the term
set out in the Notice of Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Option. 
  
 9. Tax Consequences. Set forth below is a brief summary as of the date of this Option of some of the federal tax consequences of exercise of this
Option and disposition of the Shares. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. THE OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES. 
  
 (a) Exercise of ISO. If this Option qualifies as an
ISO, there will be no regular federal income tax liability upon the exercise of the Option, although the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price will be treated as an adjustment to the
alternative minimum tax for federal tax purposes and may subject the Optionee to the alternative minimum tax in the year of exercise. 
  
 (b) Exercise of ISO Following Disability. If the Optionee ceases to be an Employee as a result of a disability that is not a total
and permanent disability as defined in Section 22(e)(3) of the Code, to the extent permitted on the date of termination, the Optionee must exercise an ISO within three months of such termination for the ISO to be qualified as an ISO. 
  
 (c) Exercise of Nonstatutory Stock Option. There may
be a regular federal income tax liability upon the exercise of a Nonstatutory Stock Option. The Optionee will be treated 

  

 -3- 

 
as having received compensation income (taxable at ordinary income tax rates) equal to the excess, if any, of the Fair Market Value of the Shares on the date
of exercise over the Exercise Price. If Optionee is an Employee or a former Employee, the Company will be required to withhold from Optionee’s compensation or collect from Optionee and pay to the applicable taxing authorities an amount in cash
equal to a percentage of this compensation income at the time of exercise, and may refuse to honor the exercise and refuse to deliver Shares if such withholding amounts are not delivered at the time of exercise. As a condition of the exercise of the
Option and if applicable in connection with the vesting of the Option, the Optionee (or in the case of the Optionee’s death, the person exercising the Option) shall make such arrangements as the Administrator may require for the satisfaction of
any applicable federal, state, local or foreign withholding tax obligations that may arise in connection with the exercise of such Option and the issuance of Shares. The Company shall not be required to issue any Shares under the Plan until such
obligations are satisfied. 
  
 (d) Disposition
of Shares. In the case of an NSO, if Shares are held for at least one year, any gain realized on disposition of the Shares will be treated as long-term capital gain for federal income tax purposes. In the case of an ISO, if Shares transferred
pursuant to the Option are held for at least one year after exercise and of at least two years after the Date of Grant, any gain realized on disposition of the Shares will also be treated as long-term capital gain for federal income tax purposes. If
Shares purchased under an ISO are disposed of within one year after exercise or two years after the Date of Grant, any gain realized on such disposition will be treated as compensation income (taxable at ordinary income rates) to the extent of the
difference between the Exercise Price and the lesser of (1) the Fair Market Value of the Shares on the date of exercise, or (2) the sale price of the Shares. Any additional gain will be taxed as capital gain, short-term or long-term depending on the
period that the ISO Shares were held. 
  
 (e)
Notice of Disqualifying Disposition of ISO Shares. If the Option granted to Optionee herein is an ISO, and if Optionee sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (1) the date two
years after the Date of Grant, or (2) the date one year after the date of exercise, the Optionee shall immediately notify the Company in writing of such disposition. Optionee agrees that Optionee may be subject to income tax withholding by the
Company on the compensation income recognized by the Optionee. 
  
 10. Entire Agreement; Governing Law. The Plan is incorporated herein by reference. The Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their
entirety all prior undertakings and agreements of the Company and Optionee with respect to the subject matter hereof, and may not be modified adversely to the Optionee’s interest except by means of a writing signed by the Company and Optionee.
This agreement is governed by the internal substantive laws but not the choice of law rules of Washington. 
  
 11. No Guarantee of Continued Service. OPTIONEE ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS
EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION 

  

 -4- 

 
OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING
SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH OPTIONEE’S RIGHT OR THE
COMPANY’S RIGHT TO TERMINATE OPTIONEE’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE. 
  
 Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option
subject to all of the terms and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the
Option. Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Option. Optionee further agrees to notify the Company upon any change
in his/her residence address. 
  

 -5- 

 AMENDED AND RESTATED 1996 STOCK PLAN 
 EXERCISE NOTICE 
  
 Xcyte Therapies, Inc. 
 1124 Columbia Street 
 Suite 130

 Seattle, WA 98104 
 Attention: Chief Financial Officer

  
 1. Exercise of Option. Effective as of today,
[DATE], the undersigned (“Optionee”) hereby elects to exercise Optionee’s option to purchase [NUMBER OF SHARES] shares of the Common Stock (the “Shares”) of Xcyte Therapies, Inc. (the
“Company”) under and pursuant to the Company’s Stock Plan (the “Plan”) and the Stock Option Agreement dated [OPTION GRANT DATE] (the “Option Agreement”). 
  
 2. Delivery of Payment. Purchaser herewith delivers to the Company the
full purchase price of the Shares, as set forth in the Option Agreement. 
  
 3. Representations of Optionee. Optionee acknowledges that Optionee has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.

  
 4. Rights as Shareholder. Until the issuance of the
Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a shareholder shall exist with respect to the Optioned
Stock, notwithstanding the exercise of the Option. The Shares shall be issued to the Optionee as soon as practicable after the Option is exercised. No adjustment shall be made for a dividend or other right for which the record date is prior to the
date of issuance except as provided in the Plan. 
  
 5.
[Intentionally left blank] 
  
 6. Tax Consultation.
Optionee understands that Optionee may suffer adverse tax consequences as a result of Optionee’s purchase or disposition of the Shares. Optionee represents that Optionee has consulted with any tax consultants Optionee deems advisable in
connection with the purchase or disposition of the Shares and that Optionee is not relying on the Company for any tax advice. 
  
 7. Restrictive Legends and Stop-Transfer Orders. 
  

 -6- 

 8. Legends. Optionee understands and agrees that the Company may cause legends that may be
required by the Company or by state or federal securities laws to be placed upon any certificate(s) evidencing ownership of the Shares. 
  
 (a) Stop-Transfer Notices. Optionee agrees that, in order to ensure compliance with the restrictions referred to herein, the
Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. 
  
 (b) Refusal to Transfer. The Company shall not be
required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to accord the right to vote or pay dividends to any
purchaser or other transferee to whom such Shares shall have been so transferred. 
  
 9. Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the
Company. Subject to the restrictions on transfer herein set forth, this Agreement shall be binding upon Optionee and his or her heirs, executors, administrators, successors and assigns. 
  
 10. Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by Optionee or by
the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall be final and binding on all parties. 
  
 11. Governing Law; Severability. This Agreement is governed by the
internal substantive laws but not the choice of law rules, of Washington. 
  
 12. Entire Agreement. The Plan and Option Agreement are incorporated herein by reference. This Agreement, the Plan, the Option Agreement and the Investment Representation Statement constitute the entire
agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Optionee with respect to the subject matter hereof, and may not be modified adversely to the
Optionee’s interest except by means of a writing signed by the Company and Optionee. 
  

 -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]